Cleveland Clinic Names Top 10 Medical Innovations in 2010

Business News Agency January 11 At the 8th Innovation Summit of the Cleveland Clinic in the United States, researchers from the Cleveland Clinic in the United States selected the top 10 medical innovations from more than 90 candidates. All ten major medical innovations have been approved by the FDA or are expected to be approved in early 2011.

1, Molecular imaging biomarkers for early diagnosis of Alzheimer's disease

The new brain imaging mixture, called AV-45, can quickly detect the early stages of brain damage in Alzheimer's patients and is expected to become the ruler of the disease.

2. Metastatic melanoma-targeting T-cell antibodies

The new anti-cancer drug ipilimumab can improve the autoimmune system more effectively against cancer. Studies have shown that ipilimumab can increase the survival rate of patients with advanced melanoma who were previously treated. The FDA is currently prioritizing the evaluation of this drug.

3, FDA approved first cancer vaccine

Provenge (Sipuleucel-T) is the first cancer vaccine that is good for survival and it stimulates the immune system to treat prostate cancer. Approval in April 2010 means that the drug can be used as soon as possible for the treatment of disease progression.

4. Jupiter Research: The Effect of Statins on Healthy Individuals

Through a large number of international studies, researchers found that cholesterol-lowering statin drugs can significantly reduce the risk of death from heart disease and normal cholesterol levels, but at the same time can cause inflammation.

5, Hepatitis C protease inhibitors

Boceprevir and telaprevir are awaiting approval. Both drugs target Hepatitis C virus and can rapidly improve the cure rate of current drugs.

6. Long-distance medical monitoring of patients with heart failure

Implantable micro-permanent monitors can monitor and communicate daily pulmonary artery pressure, just like household devices, by closely recording and transmitting weight, blood pressure, and heart rate data, with the potential to reduce the chance of hospitalization.

7, endoscopic non-incision gastric shaping weight loss

Endoscopic non-incisive gastroplasty (TOGA) is a surgical procedure that requires no incision for weight loss. The TOGA uses two flexible endoscopes to operate the instruments through the mouth to reduce the volume of the stomach.

8, exhaled nitrous oxide can diagnose asthma

A hand-held diagnostic test device accurately and accurately diagnoses asthma. This device diagnoses by measuring the level of nitrous oxide released by cells when the lungs are exhaled.

9, the first oral medication for multiple sclerosis treatment

Fingolimod has been approved by the FDA to treat the first oral drug for multiple sclerosis, the main breakthrough is clinical trials show that this drug can reduce the onset of disease and brain damage.

10, capsule endoscopy diagnosis of pediatric gastrointestinal diseases

A safe, pain-free pill-sized capsule with endoscopic imaging and X-ray imaging can take hundreds of photos and short-term video recordings in the digestive tract. The information can be sent to the data logger during operation.

Intermediates of Cladribine, Carvedilol, Lurasidone, olmesartan, Risedronate Sodium, Atazanavir, Saxagliptin, Dabigatran,Dapoxetine,Cefixime,Ceftaroline fosamil and etc.  

 

In the short span of time, we have emerged as most promising pharmaceutical intermediates manufacturers, chemical intermediates and bulk drug intermediates suppliers. Our consistent supply, quality products and dedication towards clients have opened up many international avenues for our growth.

 

In addition, the company also can follow the customer's product needs custom synthesis services

 

MAIN API  PRODUCTS   USP/BP

PRODUCT  NAME  

CAS NUMBER

SPEVIFICATION

Azithromycin

117772-70-0  

BEP

Cefpirome Sulphate sterile

84957-29-9     

USP JP16

Ceftriaxone Sodium (Sterile)

104376-79-6   

USP31

Cefotaxime     

64485-93-4  

USP30

Ciprofloxacin  HCL  

85721-33-1

USP/BP

Gentamicin sulphate  

1405-41-0  

BP

Levofloxacin  

100986-85-4  

USP27

Lincomycin   Hydrochloride  

859-18-7  

EP6.0

Moxifloxacin Hydrochloride  

186826-86-8  

USP31

Tigecycline

220620-09-7

USP

Linezolid

165800-03-3

EP

Dexamethasone   

50-02-2  

USP/BP/EP

Methylprednisolone

83-43-2  

USP/BP/EP

Dexketoprofen trometamol   

156604-79-4

BP2008

Ibuprofen

15687-27-1

BP

Metamizol

68-89-3

DAB

Sulindac  

38194-50-2   

USP/BP/EP

Naproxcinod   

163133-43-5

USP28

Tripelennamine Hydrochloride  

154-69-8   

USP28

Itraconazole  

84625-61-6   

USP/BP

Cytarabine

147-94-4     

USP31

Leucovorin Calcium

1492-18-8

USP32

Valsartan  

137862-53-4  

USP30

Telmisartan

144701-48-4  

USP31

Rosuvastatin Calcium   

147098-20-2

USP/BP

Pitavastatin Calcium

147526-32-7

USP/BP

Fluvastatin  

93957-54-1

USP31

Vinpocetine

42971-09-5  

EP6.0

Atazanavir  

198904-31-3

BP

Rosiglitazone

122320-73-4     

USP30

Esomeprazole Magnesium

161973-10-0

USP/BP

Topiramate   

 97240-79-4      

USP31

Fexofenadine HCl      

153439-40-8    

Inhouse

Bosentan    

147536-97-8    

Inhouse

D-Cysteine     

921-01-7      

Inhouse

D-Phenylalanine   

673-06-3  

Inhouse

Linagliptin                

668270-12-0  

Inhouse

Rivaroxaban

366789-02-8

USP

Saxagliptin   

361442-04-8      

USP

Vildagliptin      

274901-16-5       

USP

 

Major Pharmaceutical Intermediates

Items Descripation Structure Application
MICA ESTER
CAS No: 246035-38-1
Purity: ≥98%
246035-38-1 
For Cefixime
EHATA
CAS No: 64485-82-1
Purity: ≥98%
64485-82-1 
For Ceftazidine 
2-Chloroadenine
CAS No: 1839-18-5
 1839-18-5
 
For Cladribine, Fludarabine et al
Bicyclo(2,2,1)Heptane-2,3-di-exo-carboximide
CAS No: 14805o-29-9
14805o 29 9 
For Lurasidne
(R,R)-1,2-Bis(methanesulfonyloxy methyl)Cyclohexane
CAS No: 186204-35-3
186204-35-3
For Lurasidone
3-(Piperazin-1-yl)benzol[d] isothiazole
CAS No: 87691-87-0
87691 87 0 
For Lurasidone
Trityl olmesartan
CAS No: 144690-92-6
Purity: ≥98%

 144690-92-6
For olmesartan
3-Acetyl Pyridine
CAS No: 350-03-8

 350-03-8
For Risedronate Sodium 
3-(AceticAcid)pyridine HCL
CAS No: 6419-36-9
 6419-36-9
For Risedronate Sodium
Risedronic Acid
CAS No: 105462-24-6
105462-24-6 
For Risedronate Sodium
3-Hydroxy-1-adamantyl-D-Glycine
CAS No: 709031-29-8
 709031-29-8
For Saxagliptin
(1s,3s,5s)-3-(aminocarbonyl)-2-azabicyclo(3,1,0) hexane-2-carboxylic acid tert-butyl ester
CAS No: 361440-67-7
361440-67-7 
For Saxagliptin
(S)-N-Boc-3- hydroxy-adamantylglycine
CAS No: 361442-00-4
361442-00-4 
For Saxagliptin
2-Azabicyclo[3.1.0] hexane-3-carbonitrile, (1s,3s,5s)-
CAS No: 866083-42-3
 866083-42-3
For Saxagliptin
Ethyl 3-(pyridin-2-ylamino) propanoate
CAS No: 103041-38-9
103041-38-9 
For Dabigatran 
N-(4-Cyanophenyl) glycine
CAS No: 42288-26-6
42288-26-6 
For Dabigatran 
4-methylamino-3-nitrobenzoic Acid
CAS No: 41263-74-5
41263-74-5 
For Dabigatran 
S-3-Amino-3-phenylpropanoic acid ethyl ester HCL
CAS No: 167834-24-4
167834-24-4
 
For Dapoxetine
(S)-3-Amino-3-Phemylpropan -1-ol
CAS No: 82769-76-4

 82769-76-4
For Dapoxetine
(S)-3-Dimethylamino-3-Phemylpropanol
CAS No: 82769-75-3

82769-75-3 
For Dapoxetine
4-{4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-butynil}-α,α-dimethyl benzene acetic acid
CAS No: 832088-68-3
  For Fexofenadine HCl
Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate
CAS No:154477-54-0

154477-54-0 
For Fexofenadine HCl
5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
CAS No 461432-22-4

461432 22 4 
For Dapagliflozin
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether
CAS No :461432-23-5

 461432 23 5
For Dapagliflozin

 

APIs & Intermediates

Mica Ester,Pharma Intermediates,Ciprofloxacin Hcl Uses,Active Pharmaceutical Ingredients

NINGBO VOICE BIOCHEMIC CO. LTD , https://www.pharma-voice.com

Posted on